JENBURKT PHARMACEUTICAL L (JENBURPH) financials

JENBURKT PHARMACEUTICAL L (JENBURPH) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 1985, Jenburkt Pharmaceuticals Ltd manufactures and markets branded Pharmaceuticals and health care products[1]

Market Cap: ₹404Cr.
Current Price: ₹931
Stock P/E: 11.3
ROE: 20.2%
ROCE: 27.0%
Book Value: ₹446
Dividend Yield: 2.22%
52W High / Low: ₹1,321/911

In Jun 2026, JENBURKT PHARMACEUTICAL L (JENBURPH) reported sales ₹35.51 Cr and net profit ₹5.89 Cr.

Annual TTM: sales ₹169 Cr, net profit ₹33 Cr.

Shareholding: Promoters 46.62% (Jun 2026), FIIs 0.00% (Jun 2026), DIIs 0.12% (Jun 2026), Public 53.27% (Jun 2026), No. of Shareholders 7,103% (Jun 2026).

JENBURPH quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	41.22	36.89	41.05	35.53	45.56	43.02	44.63	35.51
Expenses	29.79	28.07	30.19	26.58	32.45	35.59	30.38	29.48
Operating Profit	11.43	8.82	10.86	8.95	13.11	7.43	14.25	6.03
OPM %	27.73%	23.91%	26.46%	25.19%	28.78%	17.27%	31.93%	16.98%
Other Income	1.85	1.58	1.88	2.06	2.08	1.82	0.40	1.51
Interest	0.12	0.11	0.11	0.11	0.11	0.12	0.13	0.13
Depreciation	0.64	0.78	0.79	0.72	0.74	0.83	0.81	0.64
Profit before tax	12.52	9.51	11.84	10.18	14.34	8.30	13.71	6.77
Tax %	23.32%	31.65%	27.87%	23.48%	29.08%	28.55%	20.86%	13.00%
Net Profit	9.60	6.51	8.54	7.79	10.16	5.93	10.85	5.89
EPS in Rs	21.75	14.75	19.35	17.65	23.02	13.44	24.58	13.35
Raw PDF	—	—	—	—	—	—	—	—

JENBURPH profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	119	109	124	137	142	152	169	169
Expenses	99	89	97	106	109	111	125	128
Operating Profit	20	20	27	30	33	40	44	41
OPM %	17%	18%	22%	22%	23%	27%	26%	24%
Other Income	4	4	5	5	5	7	6	6
Interest	1	0	0	0	0	0	0	0
Depreciation	2	2	2	2	2	3	3	3
Profit before tax	21	22	30	33	35	44	47	43
Tax %	30%	24%	25%	25%	26%	27%	25%	—
Net Profit	15	16	22	25	26	32	35	33
EPS in Rs	32.40	35.95	48.59	55.76	58.87	72.64	78.72	74.39
Dividend Payout %	25%	28%	25%	26%	26%	25%	26%	—

JENBURPH balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	5	5	5	5	4	4	4	4
Reserves	73	75	94	113	118	141	167	193
Borrowings	7	3	5	7	3	0	4	2
Other Liabilities	18	21	17	18	16	19	19	26
Total Liabilities	103	104	120	143	141	164	195	225
Fixed Assets	10	12	11	11	10	10	15	19
CWIP	1	0	0	0	1	1	40	46
Investments	5	4	7	8	11	17	21	27
Other Assets	87	88	103	123	119	136	120	132
Total Assets	103	104	120	143	141	164	195	225

JENBURPH cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	13	15	19	9	17	8	28	27
Cash from Investing Activity	-11	-3	-19	-1	3	-1	-17	-19
Cash from Financing Activity	-2	-11	-1	-6	-21	-7	-8	-9
Net Cash Flow	0	1	-0	3	-1	0	3	-2
Free Cash Flow	11	11	18	7	15	6	8	13
CFO/OP	80%	104%	127%	62%	83%	49%	102%	88%

JENBURPH shareholding pattern (%)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	46.71%	46.69%	46.68%	46.67%	46.66%	46.65%	46.64%	46.62%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
DIIs	0.00%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%
Public	53.28%	53.20%	53.20%	53.21%	53.22%	53.24%	53.24%	53.27%
No. of Shareholders	6,628	6,901	6,987	6,712	6,855	7,163	6,999	7,103

JENBURPH key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	68	55	47	45	45	50	50	53
Inventory Days	99	120	92	115	92	103	109	154
Days Payable	66	58	56	83	67	75	100	91
Cash Conversion Cycle	101	117	83	77	70	78	59	115
Working Capital Days	35	32	17	16	31	36	31	41
ROCE %	37%	26%	24%	26%	27%	26%	27%	27%

JENBURPHUpdated 30 Sept 2026, 17:43

Jenburkt Pharmaceutical L

JENBURPHUpdated 30 Sept 2026, 17:43

Market Cap

₹404Cr.

Current Price

₹931

High / Low

₹1,321/911

Stock P/E

11.3

ROE20.2%

ROCE27.0%

Book Value₹446

Face Value₹10.0

Dividend Yield2.22%

About

Incorporated in 1985, Jenburkt Pharmaceuticals Ltd manufactures and markets branded Pharmaceuticals and health care products[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	29.18	0.07	22.22	1.04	0.5	7.43	27.73	5.37	12.17
Sep 2023	38.29	0.07	29.19	1.1	0.59	9.54	23.27	7.32	16.59
Dec 2023	35.66	0.07	28.47	1.35	0.63	7.84	31.12	5.4	12.24
Mar 2024	38.84	0.06	28.99	1.19	0.62	10.36	23.94	7.88	17.86
Jun 2024	32.54	0.11	23.26	1.41	0.52	10.06	26.34	7.42	16.81
Sep 2024	41.22	0.12	29.79	1.85	0.64	12.52	23.32	9.6	21.75
Dec 2024	36.89	0.11	28.07	1.58	0.78	9.51	31.65	6.51	14.75
Mar 2025	41.05	0.11	30.19	1.88	0.79	11.84	27.87	8.54	19.35
Jun 2025	35.53	0.11	26.58	2.06	0.72	10.18	23.48	7.79	17.65
Sep 2025	45.56	0.11	32.45	2.08	0.74	14.34	29.08	10.16	23.02
Dec 2025	43.02	0.12	35.59	1.82	0.83	8.3	28.55	5.93	13.44
Mar 2026	44.63	0.13	30.38	0.4	0.81	13.71	20.86	10.85	24.58
Jun 2026	35.51	0.13	29.48	1.51	0.64	6.77	13	5.89	13.35

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	85	0	70	2	3	14	33	10	20.76
Mar 2016	94	0	77	3	2	17	36	11	23.19
Mar 2017	103	0	84	3	2	20	34	14	29.06
Mar 2018	115	0	91	3	2	25	32	17	37.5
Mar 2019	123	0	98	3	1	27	26	20	43.14
Mar 2020	119	1	99	4	2	21	30	15	32.4
Mar 2021	109	0	89	4	2	22	24	16	35.95
Mar 2022	124	0	97	5	2	30	25	22	48.59
Mar 2023	137	0	106	5	2	33	25	25	55.76
Mar 2024	142	0	109	5	2	35	26	26	58.87
Mar 2025	152	0	111	7	3	44	27	32	72.64
Mar 2026	169	0	125	6	3	47	25	35	78.72
TTM	169	0	128	6	3	43	—	33	74.39

Shareholding pattern

As of Jun 2026%

Holder	Share
Promoters	46.62%
DIIs	0.12%
Public	53.27%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Sep 2023	47.42%	1.38%	0%	51.21%
Dec 2023	47.39%	0%	0%	52.63%
Mar 2024	47.23%	0%	0%	52.78%
Jun 2024	46.71%	0%	0%	53.29%
Sep 2024	46.71%	0%	0%	53.28%
Dec 2024	46.69%	0%	0.12%	53.2%
Mar 2025	46.68%	0%	0.12%	53.2%
Jun 2025	46.67%	0%	0.12%	53.21%
Sep 2025	46.66%	0%	0.12%	53.22%
Dec 2025	46.65%	0%	0.12%	53.24%
Mar 2026	46.64%	0%	0.12%	53.24%
Jun 2026	46.62%	0%	0.12%	53.27%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	5	29	7	21	61	12	0	0	49	61
Mar 2016	5	36	5	12	58	12	0	1	45	58
Mar 2017	5	50	6	16	76	11	0	2	64	76
Mar 2018	5	57	0	16	77	10	0	5	62	77
Mar 2019	5	73	7	18	103	10	1	5	87	103
Mar 2020	5	75	3	21	104	12	0	4	88	104
Mar 2021	5	94	5	17	120	11	0	7	103	120
Mar 2022	5	113	7	18	143	11	0	8	123	143
Mar 2023	4	118	3	16	141	10	1	11	119	141
Mar 2024	4	141	0	19	164	10	1	17	136	164
Mar 2025	4	167	4	19	195	15	40	21	120	195
Mar 2026	4	193	2	26	225	19	46	27	132	225

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	9	1	1	11
Mar 2016	8	0	-5	2
Mar 2017	10	-10	1	1
Mar 2018	16	1	-18	-1
Mar 2019	13	-11	-2	0
Mar 2020	15	-3	-11	1
Mar 2021	19	-19	-1	0
Mar 2022	9	-1	-6	3
Mar 2023	17	3	-21	-1
Mar 2024	8	-1	-7	0
Mar 2025	28	-17	-8	3
Mar 2026	27	-19	-9	-2

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	32	23	32	40	68	55	47	45	45	50	50	53
Inventory Days	107	109	128	73	99	120	92	115	92	103	109	154
Days Payable	54	44	72	44	66	58	56	83	67	75	100	91
Cash Conversion Cycle	85	88	89	69	101	117	83	77	70	78	59	115
Working Capital Days	-11	6	10	25	35	32	17	16	31	36	31	41
ROCE %	42%	40%	39%	42%	37%	26%	24%	26%	27%	26%	27%	27%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of JENBURKT PHARMACEUTICAL L (JENBURPH)?

The reported market capitalisation for JENBURKT PHARMACEUTICAL L (JENBURPH) is ₹404Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of JENBURPH?

The current price shown for JENBURKT PHARMACEUTICAL L (JENBURPH) on Fincrux is ₹931 with a 52-week high/low of ₹1,321/911.

What is the P/E ratio of JENBURKT PHARMACEUTICAL L (JENBURPH)?

The stock P/E for JENBURKT PHARMACEUTICAL L (JENBURPH) is 11.3 on Fincrux, with ROE at 20.2% and ROCE at 27.0%.

What were JENBURPH latest quarterly results?

For Jun 2026, JENBURKT PHARMACEUTICAL L (JENBURPH) reported sales ₹35.51 Cr and net profit ₹5.89 Cr (figures in ₹ crore unless noted).

What are JENBURPH annual sales and net profit?

For TTM, JENBURKT PHARMACEUTICAL L (JENBURPH) shows sales of ₹169 Cr and net profit of ₹33 Cr on the Fincrux profit & loss statement.

Who owns JENBURKT PHARMACEUTICAL L (JENBURPH)?

Latest shareholding for JENBURKT PHARMACEUTICAL L (JENBURPH) on Fincrux: Promoters 46.62% (Jun 2026), FIIs 0.00% (Jun 2026), DIIs 0.12% (Jun 2026), Public 53.27% (Jun 2026), No. of Shareholders 7,103% (Jun 2026).

Where can I find JENBURKT PHARMACEUTICAL L (JENBURPH) financials?

JENBURKT PHARMACEUTICAL L (JENBURPH) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show JENBURPH balance sheet and cash flow?

Yes. The JENBURKT PHARMACEUTICAL L (JENBURPH) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 30 September 2026 at 17:43